Development of an in-vivo active reversible butyrylcholinesterase inhibitor

HIGHLIGHTS

• who: Urban Košak from the FacultyUniversity of have published the research work: Development of an in-vivo active reversible butyrylcholinesterase inhibitor, in the Journal: Scientific Reports Scientific Reports of 23/Nov/1986
• what: Among the major reason for limited brain exposure of compounds designed to be active in the central nervous system is their low passive permeability combined with active efflux by membrane_transport proteins like P-glycoprotein or breast cancer resistance protein (BCRP) and high molecular weight42.
• how: Given these facts to obtain the true affinity of the pure enantiomers of compound . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.